🐂 Not all bull runs are created equal. November’s AI picks include 5 stocks up +20% eachUnlock Stocks

Stocks - Moderna, Apple Rise Premarket; Hasbro Falls

Published 07/27/2020, 08:08 AM
Updated 07/27/2020, 08:09 AM
© Reuters.
JPM
-
AAPL
-
BIIB
-
MS
-
AVY
-
PCG
-
HAS
-
BLMN
-
AZN
-
MRNA
-

By Peter Nurse 

Investing.com -- Stocks in focus in premarket trade on Monday, July 27th. Please refresh for updates.

  • Moderna (NASDAQ:MRNA) stock rose 8.2% after the drugmaker said Sunday it has received an additional $472 million from the U.S. government to support the development of its novel coronavirus vaccine. It also received $483 million in April.

  • Hasbro (NASDAQ:HAS) stock fell 3.2% after the toymaker reported a net loss of $33.9 million in the second quarter, with revenues down 29%. The company cited “temporary store closures, product shortages in fast-growing categories and lower retail inventory" due to the pandemic.

  • Apple (NASDAQ:AAPL) stock rose 1.2% despite being removed from JPMorgan’s Focus List. The investment bank keeps its overweight rating, but says "investors looking for further upside have to focus on the longer-term earnings trajectory rather than expect near-term upside." That said, the bank expects an earnings beat when Apple reports this week.

  • Biogen (NASDAQ:BIIB) stock rose 2.6% after Morgan Stanley (NYSE:MS) upgraded its investment stance on the drugmaker to ‘overweight’ from ‘underweight’, citing prospects for the success of its Alzheimer’s drug aducanumab.

  • Pacific Gas & Electric (NYSE:PCG) stock rose 0.4% after a Barron’s report suggested that the utility looks undervalued after coming out of bankruptcy protection.

  • Bloomin Brands (NASDAQ:BLMN) stock rose 3.6% after investment bank JPMorgan (NYSE:JPM) upgraded its stance on the restaurant holding company to ‘overweight’, seeing the company as “a survivor in the space.”

  • AstraZeneca (NYSE:AZN) ADRs rose 0.5% after the U.K.-based pharma giant agreed to pay up to $6 billion to Japanese drugmaker Daiichi Sankyo, in the second multibillion cancer drug collaboration in a year between the two companies.

  • Avery Dennison (NYSE:AVY)stock rose 1.3% after reporting a second-quarter earnings beat despite organic sales falling 13.7%.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.